Beranda › Meduloblastoma
Uji klinis Meduloblastoma yang merekrut di AS
24 studi untuk Meduloblastoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Washington, DC9 studi
- St. Louis, MO6 studi
- Houston, TX4 studi
- New York City, NY4 studi
- Philadelphia, PA4 studi
- Durham, NC4 studi
- Miami, FL4 studi
- Seattle, WA4 studi
- Tampa, FL4 studi
- Memphis, TN3 studi
- Chicago, IL3 studi
- Ann Arbor, MI3 studi
- Columbus, OH3 studi
- Boston, MA3 studi
- Cincinnati, OH3 studi
- Austin, TX3 studi
- Little Rock, AR3 studi
- Hartford, CT3 studi
- San Diego, CA3 studi
- San Francisco, CA3 studi
- Charlotte, NC3 studi
- Minneapolis, MN3 studi
- St. Petersburg, FL3 studi
- Dallas, TX3 studi
- Orlando, FL3 studi
- Mountain View, CA3 studi
Berdasarkan negara bagian
- Alabama3 studi
- Arkansas3 studi
- California6 studi
- Connecticut3 studi
- Distrik Columbia7 studi
- Florida6 studi
- Georgia3 studi
- Illinois3 studi
- Kentucky3 studi
- Maryland4 studi
- Massachusetts3 studi
- Michigan4 studi
- Minnesota3 studi
- Missouri6 studi
- New Jersey3 studi
- New York5 studi
- North Carolina4 studi
- Ohio3 studi
- Pennsylvania5 studi
- Tennessee5 studi
- Texas8 studi
- Washington4 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Menerima pesertaFase 1/2
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07346157Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback
Menerima peserta
Usia 10 hingga 25 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07830134Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Menerima pesertaFase 2
59 Months · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05535166GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07087002Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Menerima pesertaFase 2
Hingga usia 19 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT01356290HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Menerima pesertaFase 1
36 Months – 22 Years · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
Menerima pesertaFase 1
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07390539Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Menerima pesertaStudi observasional
Usia 3 hingga 50 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07242963Digoxin Medulloblastoma Study
Menerima pesertaFase 2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06701812A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Menerima pesertaFase 3
Usia 4 hingga 21 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05382338PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06161519DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Menerima pesertaFase 2
Hingga usia 21 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT04696029Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Menerima peserta
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05057702Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Menerima pesertaFase 1
Usia 4 hingga 30 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06514898Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Menerima pesertaFase 1
Usia 2 hingga 25 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06624371Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Menerima pesertaFase 1/2
Usia 4 hingga 39 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT05278208A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Menerima pesertaFase 1
Usia 3 hingga 22 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT07698899CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT07085325Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06193759Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Menerima pesertaFase 1
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT04185038Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Menerima pesertaFase 1
Usia 3 hingga 25 · Semua jenis kelamin · Diperbarui 9 Jan 2026 · NCT05106296Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Des 2025 · NCT0454108268-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Menerima pesertaFase 4
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 21 Nov 2025 · NCT04081701Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.